Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
Omar Khalil rejoined Santé in 2020, concentrates on the biotechnology and medical technology spaces, and manages the Boston Office. Prior to that, he held senior leadership roles with Baxter International, Baxalta (now part of Takeda) and Kaléo, a commercial-stage biopharmaceutical company developing a novel drug delivery platform primarily focused in Allergy & Immunology. He has managed and led businesses ranging from early clinical development, commercial launch and scaling to more than $3 Billion in annual sales. He spent four years at Santé as a Principal, investing Funds I and II. Earlier in his career, he worked at McKinsey & Company in the healthcare practice, where he served leading medical device and pharmaceutical companies. He received his MSE and BSE in Biomedical Engineering summa cum laude from the University of Michigan with a concentration in Tissue Engineering.
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

However, if you would like to share the information in this article, you may use the link below:
vision-care.medicaltechoutlook.com/cxo-awards/top-10-vc-firms-investing-in-medtech-2022/omar-khalil/
